Drug Profile
Donepezil transdermal patch - NAL Pharma
Alternative Names: NAL-8812Latest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Antidementias; Indans; Nootropics; Piperidines; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Alzheimer's disease
Highest Development Phases
- Clinical Phase Unknown Alzheimer's disease
Most Recent Events
- 26 May 2022 Donepezil transdermal patch is still in clinical trials in Alzheimer's disease in Hong Kong (NAL Pharma pipeline, May 2022)
- 28 Jun 2019 No recent reports of development identified for clinical-Phase-Unknown development in Alzheimer's-disease in Hong Kong (Transdermal, Patch)